PDE6α Activators encompass a range of chemical compounds that indirectly augment the functional activity of PDE6α, primarily through the modulation of cyclic nucleotide levels within cells. Sildenafil, Tadalafil, Vardenafil, Hydrochloride Salt, and Zaprinast (M&B 22948) function as selective inhibitors of phosphodiesterase type 5 (PDE5), leading to an elevation in cyclic guanosine monophosphate (cGMP) levels. This rise in cGMP indirectly enhances PDE6α activity, which is crucial in the phototransduction process in retinal cells. These compounds ensure that cGMP, a substrate of PDE6α, is abundantly available, thereby facilitating the role of PDE6α in the visual cycle. Similarly, Ibudilast and Rolipram, through their inhibition of PDE4, may also contribute to increased cGMP levels, indirectly supporting PDE6α's function in the retina. These compounds, while primarily increasing cyclic adenosine monophosphate (cAMP), can have a secondary effect on cGMP concentrations, thus influencing PDE6α activity.
Further, compounds like Anagrelide, Milrinone, and Cilostazol, which inhibit PDE3, may indirectly raise cGMP levels, enhancing PDE6α's role in phototransduction. Their primary action on cAMP levels has a cascading effect that can benefit cGMP dynamics, indirectly supporting PDE6α activity. Dipyridamole, with its inhibitory effect on both PDE5 and PDE6, ensures an increase in cGMP levels, thus indirectly promoting PDE6α's functionality. This mechanism is particularly significant in the retina, where PDE6α plays a pivotal role. Additionally, Theophylline and Pentoxifylline, as non-selective PDE inhibitors, contribute to the increased availability of cGMP. By inhibiting a broad range of phosphodiesterases, these compounds elevate cGMP levels, indirectly fostering an environment conducive to enhanced PDE6α activity. Collectively, these PDE6α Activators, by increasing cGMP levels through various mechanisms, indirectly facilitate the enhancement of PDE6α-mediated functions crucial for vision, particularly in the context of phototransduction in retinal cells.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Tadalafil, by inhibiting PDE5, leads to increased cGMP levels, similar to Sildenafil. This cGMP elevation indirectly enhances PDE6α activity in retinal photoreceptors. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil, Hydrochloride Salt's inhibition of PDE5 results in raised cGMP concentrations, indirectly enhancing PDE6α activity, thereby affecting phototransduction in the retina. | ||||||
Ibudilast | 50847-11-5 | sc-203080 | 10 mg | $218.00 | 1 | |
Ibudilast inhibits PDE4 and PDE10A but also increases cGMP levels indirectly, thereby potentially enhancing PDE6α activity in retinal photoreceptors. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, by inhibiting PDE4, indirectly leads to increased cAMP and possibly cGMP levels, thereby potentially enhancing PDE6α activity in the retina. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide, a PDE3 inhibitor, may indirectly increase cGMP levels, which could enhance PDE6α activity in the phototransduction process. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a PDE3 inhibitor, can indirectly lead to elevated cGMP levels, potentially enhancing PDE6α activity in the retina. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol inhibits PDE3 and increases cAMP levels, which may indirectly influence cGMP levels and enhance PDE6α activity in retinal photoreceptors. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole, by inhibiting PDE5 and PDE6, can lead to increased cGMP levels, indirectly promoting PDE6α activity, especially in the retina. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective PDE inhibitor, may raise cGMP levels indirectly, enhancing PDE6α activity in the phototransduction pathway. | ||||||
Pentoxifylline | 6493-05-6 | sc-203184 | 1 g | $20.00 | 3 | |
Pentoxifylline, by inhibiting various PDEs, can increase cGMP levels, which indirectly could enhance PDE6α activity in the retina. | ||||||